Search - tctmd.com

Displaying 21 - 40 of 626

Sort: Relevancy | Date

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

Todd Neale

October 18, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

Shelley Wood

October 07, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

Advertisement

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

TCTMD’s Top 10 Most Popular Stories for October 2016

Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content